KR100919141B1 - 치환 피페라진 화합물 및 그의 지방산 산화 저해제로서의용도 - Google Patents

치환 피페라진 화합물 및 그의 지방산 산화 저해제로서의용도 Download PDF

Info

Publication number
KR100919141B1
KR100919141B1 KR1020047000898A KR20047000898A KR100919141B1 KR 100919141 B1 KR100919141 B1 KR 100919141B1 KR 1020047000898 A KR1020047000898 A KR 1020047000898A KR 20047000898 A KR20047000898 A KR 20047000898A KR 100919141 B1 KR100919141 B1 KR 100919141B1
Authority
KR
South Korea
Prior art keywords
compound
yloxy
formula
methyl
optionally substituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020047000898A
Other languages
English (en)
Korean (ko)
Other versions
KR20040029374A (ko
Inventor
이브라힘프라바
셍크케빈
엘제인엘파티
팔레벤카타
자블록키제프
레더케니스
Original Assignee
씨브이 쎄러퓨틱스, 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 씨브이 쎄러퓨틱스, 인코포레이티드 filed Critical 씨브이 쎄러퓨틱스, 인코포레이티드
Publication of KR20040029374A publication Critical patent/KR20040029374A/ko
Application granted granted Critical
Publication of KR100919141B1 publication Critical patent/KR100919141B1/ko
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
    • C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
    • C07D263/56—Benzoxazoles; Hydrogenated benzoxazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D263/57—Aryl or substituted aryl radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/06—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62—Benzothiazoles
    • C07D277/64—Benzothiazoles with only hydrocarbon or substituted hydrocarbon radicals attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Transplantation (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Lubricants (AREA)
  • Pyridine Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Paper (AREA)
  • Emulsifying, Dispersing, Foam-Producing Or Wetting Agents (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
KR1020047000898A 2001-07-19 2002-07-18 치환 피페라진 화합물 및 그의 지방산 산화 저해제로서의용도 Expired - Fee Related KR100919141B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US30662101P 2001-07-19 2001-07-19
US60/306,621 2001-07-19
PCT/US2002/022897 WO2003008411A1 (en) 2001-07-19 2002-07-18 Substituted piperazine compounds and their use as fatty acid oxidation inhibitors

Publications (2)

Publication Number Publication Date
KR20040029374A KR20040029374A (ko) 2004-04-06
KR100919141B1 true KR100919141B1 (ko) 2009-09-25

Family

ID=23186103

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020047000898A Expired - Fee Related KR100919141B1 (ko) 2001-07-19 2002-07-18 치환 피페라진 화합물 및 그의 지방산 산화 저해제로서의용도

Country Status (21)

Country Link
US (1) US6930111B2 (enExample)
EP (1) EP1406898B1 (enExample)
JP (1) JP2004537554A (enExample)
KR (1) KR100919141B1 (enExample)
CN (1) CN1533388A (enExample)
AT (1) ATE292633T1 (enExample)
AU (1) AU2008202958A1 (enExample)
CA (1) CA2454059A1 (enExample)
DE (1) DE60203623T2 (enExample)
DK (1) DK1406898T3 (enExample)
ES (1) ES2236557T3 (enExample)
HU (1) HUP0402088A3 (enExample)
IL (1) IL159897A0 (enExample)
MX (1) MXPA04000565A (enExample)
NO (1) NO327635B1 (enExample)
NZ (1) NZ530705A (enExample)
PL (1) PL368529A1 (enExample)
PT (1) PT1406898E (enExample)
RU (1) RU2300533C2 (enExample)
WO (1) WO2003008411A1 (enExample)
ZA (1) ZA200400404B (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7001909B2 (en) * 2001-07-19 2006-02-21 Cv Therapeutics, Inc. Substituted heterocyclic compounds
NZ536678A (en) 2002-05-21 2007-01-26 Cv Therapeutics Inc Administration of a partial fatty acid inhibitor such as ranolazine for the treatment of diabetes
US8822473B2 (en) * 2002-05-21 2014-09-02 Gilead Sciences, Inc. Method of treating diabetes
PL375256A1 (en) 2002-08-09 2005-11-28 Astra Zeneca Ab 1,2,4-oxadiazoles as modulators of metabotropic glutamate receptor-5
AU2003264018A1 (en) * 2002-08-09 2004-02-25 Astrazeneca Ab Compounds having an activity at metabotropic glutamate receptors
US20040132726A1 (en) * 2002-08-09 2004-07-08 Astrazeneca Ab And Nps Pharmaceuticals, Inc. New compounds
US7125876B2 (en) * 2002-12-05 2006-10-24 Cv Therapeutics, Inc. Substituted heterocyclic compounds
EP1806346B1 (en) * 2002-12-05 2009-07-22 Cv Therapeutics, Inc. Substituted piperazine compounds and their use as fatty acid oxidation inhibitors
EP1578737B1 (en) 2003-01-03 2009-09-16 Cv Therapeutics, Inc. Substituted heterocyclic compounds
AU2004209522A1 (en) * 2003-01-17 2004-08-19 Gilead Palo Alto, Inc. Substituted heterocyclic compounds useful in the treatment of cardiovascular diseases
KR20060065586A (ko) * 2003-06-23 2006-06-14 씨브이 쎄러퓨틱스, 인코포레이티드 지방산 산화 저해제로서의, 피페라진 및 피페리딘의 우레아유도체
CA2550257A1 (en) * 2003-12-18 2005-07-07 Cv Therapeutics, Inc. 1-akan-2-ol substituted piperazine and piperidine compounds
WO2005068020A1 (en) * 2004-01-02 2005-07-28 Advanced Cardiovascular Systems, Inc. High-density lipoprotein coated medical devices
WO2006029179A2 (en) * 2004-09-08 2006-03-16 Cv Therapeutics, Inc. Substituted piperazine compounds and their use as fatty acid oxidation inhibitors
WO2008023248A2 (en) 2006-08-24 2008-02-28 Wockhardt Research Centre Novel macrolides and ketolides having antimicrobial activity
US8088920B2 (en) * 2008-03-31 2012-01-03 Hoffmann-La Roche Inc. 3-trifluoromethyl-pyrazine-2-carboxylic acid amide derivatives as HDL-cholesterol raising agents
SI3135672T1 (sl) * 2008-10-10 2020-07-31 Vm Discovery, Inc. Sestavki in postopki za zdravljenje motenj, bolečin in drugih bolezni povezanih z uporabo alkohola
AU2010248948A1 (en) * 2009-05-14 2011-12-01 Gilead Sciences, Inc. Ranolazine for the treatment of CNS disorders
WO2011115150A1 (ja) * 2010-03-18 2011-09-22 興和株式会社 ベンゾチアジン化合物の製造方法
CN111285819A (zh) * 2018-12-07 2020-06-16 江苏恩华药业股份有限公司 一种苯并噁唑类化合物及其应用
WO2023023995A1 (zh) * 2021-08-25 2023-03-02 苏州大学 一种防治心肌缺血后心功能衰竭的药物及其应用

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1133989A (en) * 1964-12-08 1968-11-20 Chugai Pharmaceutical Co Ltd Theophylline derivatives, their salts and process for preparing the same
DE2834114A1 (de) * 1978-08-01 1980-02-14 Schering Ag Polyalkoxyphenylpyrrolidone iii, verfahren zu ihrer herstellung und ihre verwendung
US4567264A (en) * 1983-05-18 1986-01-28 Syntex (U.S.A.) Inc. Cardioselective aryloxy- and arylthio- hydroxypropylene-piperazinyl acetanilides which affect calcium entry
JPS6137765A (ja) * 1984-07-19 1986-02-22 サンド・アクチエンゲゼルシヤフト ３‐アミノプロポキシアリール誘導体
US4723014A (en) * 1986-11-19 1988-02-02 Warner-Lambert Company Process for the preparation of 2-substituted-1,4-dihydropyridines
DE3723648A1 (de) * 1987-07-17 1989-01-26 Sandoz Ag Indol-derivate, ihre herstellung und sie enthaltende arzneimittel
JPH0699399B2 (ja) * 1988-10-06 1994-12-07 三井東圧化学株式会社 新規複素環化合物およびそれを有効成分として含有する製癌剤効果増強剤
JPH02268162A (ja) * 1989-04-10 1990-11-01 Fujisawa Pharmaceut Co Ltd ジフェニルピリジン誘導体
MX9308025A (es) * 1992-12-22 1994-08-31 Lilly Co Eli Compuestos inhibidores de la proteasa del virus dela inmunodeficiencia humana, procedimiento para supreparacion y formulacion farmaceutica que los contiene.
WO1998021190A1 (en) * 1996-11-14 1998-05-22 American Home Products Corporation Substituted tetrahydro-1,3,5-triazin-2[1h]-thiones as anti-atherosclerotic agents
TWI287018B (en) * 1999-09-13 2007-09-21 Wyeth Corp Glucopyranosides conjugates of 2-(4-hydroxy-phenyl)-3-methyl-1-[4-(2-amin-1-yl-ethoxy)-benzyl]-1H-indol-5-ols
SE9904765D0 (sv) * 1999-12-23 1999-12-23 Astra Ab Pharmaceutically-useful compounds
US6552023B2 (en) * 2000-02-22 2003-04-22 Cv Therapeutics, Inc. Aralkyl substituted piperazine compounds
US6451798B2 (en) * 2000-02-22 2002-09-17 Cv Therapeutics, Inc. Substituted alkyl piperazine derivatives
WO2001062749A1 (en) * 2000-02-22 2001-08-30 Cv Therapeutics, Inc. Substituted piperazine compounds
BR0108592A (pt) * 2000-02-22 2004-06-29 Cv Therapeutics Inc Compostos de piperazina substituìda
US6638970B2 (en) * 2000-02-22 2003-10-28 Cv Therapeutics, Inc. Substituted alkylene diamine compounds
SE0003795D0 (sv) * 2000-10-20 2000-10-20 Astrazeneca Ab Pharmaceutically useful compounds
US6573264B1 (en) * 2000-10-23 2003-06-03 Cv Therapeutics, Inc. Heteroaryl alkyl piperazine derivatives

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
논문 J.Med.Chem.(1997)

Also Published As

Publication number Publication date
CA2454059A1 (en) 2003-01-30
EP1406898A1 (en) 2004-04-14
HUP0402088A2 (hu) 2005-02-28
AU2002322527A2 (en) 2003-03-03
NO327635B1 (no) 2009-09-07
HK1064374A1 (en) 2005-01-28
US6930111B2 (en) 2005-08-16
IL159897A0 (en) 2004-06-20
NZ530705A (en) 2005-08-26
MXPA04000565A (es) 2005-06-17
HUP0402088A3 (en) 2010-03-29
ES2236557T3 (es) 2005-07-16
AU2008202958A1 (en) 2008-07-31
DE60203623T2 (de) 2006-01-19
JP2004537554A (ja) 2004-12-16
PT1406898E (pt) 2005-08-31
NO20040234L (no) 2004-03-18
DK1406898T3 (da) 2005-05-30
DE60203623D1 (de) 2005-05-12
EP1406898B1 (en) 2005-04-06
ZA200400404B (en) 2004-10-14
RU2300533C2 (ru) 2007-06-10
KR20040029374A (ko) 2004-04-06
RU2004104951A (ru) 2005-06-27
ATE292633T1 (de) 2005-04-15
PL368529A1 (en) 2005-04-04
CN1533388A (zh) 2004-09-29
AU2002322527B2 (en) 2008-04-17
WO2003008411A1 (en) 2003-01-30
US20030181352A1 (en) 2003-09-25

Similar Documents

Publication Publication Date Title
KR100919141B1 (ko) 치환 피페라진 화합물 및 그의 지방산 산화 저해제로서의용도
US7001909B2 (en) Substituted heterocyclic compounds
US7026321B2 (en) Substituted heterocyclic compounds
AU2003300827B2 (en) Substituted piperazine compounds and their use as fatty acid oxidation inhibitors
US7056924B2 (en) Substituted heterocyclic compounds
AU2002322527C1 (en) Substituted piperazine compounds and their use as fatty acid oxidation inhibitors
AU2002322527A1 (en) Substituted piperazine compounds and their use as fatty acid oxidation inhibitors
HK1064374B (en) Substituted piperazine compounds and their use as fatty acid oxidation inhibitors
HK1083492B (en) Substituted piperazine compounds and their use as fatty acid oxidation inhibitors
KR20070051305A (ko) 치환된 피페라진 화합물 및 지방산 산화 저해제로서의 이의용도

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

AMND Amendment
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

A201 Request for examination
AMND Amendment
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

AMND Amendment
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E601 Decision to refuse application
PE0601 Decision on rejection of patent

St.27 status event code: N-2-6-B10-B15-exm-PE0601

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

AMND Amendment
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

J201 Request for trial against refusal decision
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PJ0201 Trial against decision of rejection

St.27 status event code: A-3-3-V10-V11-apl-PJ0201

PB0901 Examination by re-examination before a trial

St.27 status event code: A-6-3-E10-E12-rex-PB0901

B701 Decision to grant
PB0701 Decision of registration after re-examination before a trial

St.27 status event code: A-3-4-F10-F13-rex-PB0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

LAPS Lapse due to unpaid annual fee
PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20120922

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20120922